Emma Linderoth,Natasja Nielsen Viller,Robert Adam Uger,Penka Slavcheva Slavova-Petrova
申请号：
US16344985
公开号：
US20190269756A1
申请日:
2017.11.01
申请国别(地区):
US
年份:
2019
代理人:
摘要：
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
